Debug Stats | ### Total Build Time: 16 ms 28.413 KB CONCEPT_NAME gt=1 ms Completed: 1 ms rowSize= 346 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 301 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=1 ms Completed: 1 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=1 ms Completed: 1 ms rowSize= 106 bytesCONCEPT_GENES gt=10 ms Completed: 10 ms rowSize= 26.449 KBCONCEPT_XREFS gt=3 ms Completed: 3 ms rowSize= 1.158 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Genes (18)
Species: human : 18 | |
Human | CTNNBIP1 | 56998 | catenin, beta interacting protein 1 | Real-time RT-PCR showed markedly reduced ICAT transcript levels (<or=20% relative to normal skin and benign melanocytic nevi) in 28/36 malignant melanomas (78%), including 13/14 tumors with LOH on 1p36. | Human | XAF1 | 54739 | XIAP associated factor 1 | Our results showed that XAF1 expression in melanoma tissues was significantly reduced compared with benign melanocytic nevi (p<0.05). XAF1 expression in melanoma tissues was significantly reduced compared with benign melanocytic nevi | Human | PHLDA1 | 22822 | pleckstrin homology-like domain, family A, member 1 | Monoclonal antibodies produced against the PHLDA1 protein revealed homogeneous strong expression by benign melanocytic nevi, and progressively reduced expression in primary and metastatic melanomas in vivo. | Human | SLC2A1 | 6513 | solute carrier family 2 (facilitated glucose transporter), member 1 | results suggest that glucose transporter Glut-1 expression can significantly discriminate between human malignant melanoma and benign melanocytic nevi | Human | PRPH | 5630 | peripherin | We evaluated by immunohistochemistry 74 cutaneous melanocytic lesions including primary invasive malignant melanoma (IMM), melanoma in situ (MIS), atypical nevus (nevus with architectural disorder and cytologic atypia of melanocytes) (AN), spindle and epithelioid cell nevus (Spitz nevus) (SN), blue nevus (BN), and common intradermal benign melanocytic nevus (BMN) for expression of peripherin. | Human | NFKB1 | 4790 | nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | NFkappaB is differentially expressed in melanocytes of normal skin, benign intradermal naevus and human metastatic melanoma biopsies | Human | NAB2 | 4665 | NGFI-A binding protein 2 (EGR1 binding protein 2) | The fact that only one of six benign melanocytic nevi examined showed evidence of Mader expression suggests that over-expression of Mader protein may be associated with the malignant transformation of melanocytes. | Human | MTAP | 4507 | methylthioadenosine phosphorylase | In summary, we demonstrate significant inverse correlation between MTAP protein expression and progression of melanocytic tumors as the amount of MTAP protein staining decreases from benign melanocytic nevi to metastatic melanomas. MTAP expression was further analyzed in vivo by immunohistochemical staining of 38 tissue samples of benign melanocytic nevi, melanomas, and melanoma metastases. | Human | MCM2 | 4171 | minichromosome maintenance complex component 2 | MCM protein 2 is present in melanocytes from benign nevi, dysplastic nevi, primary cutaneous melanomas, and cutaneous melanoma metastases | Human | IL3 | 3562 | interleukin 3 (colony-stimulating factor, multiple) | In order to determine whether there is a differential expression of this MC chemotactic/mitogenic factor with tumor progression in vivo, we evaluated by immunohistochemistry 85 melanocytic lesions including primary invasive malignant melanoma (PIMM), melanoma in situ (MMIS), and ordinary intradermal benign melanocytic nevi (BMN) for expression of IL-3. | Human | IFNA17 | 3451 | interferon, alpha 17 | We have analyzed 54 benign melanocytic nevi and 6 DMN for loss of heterozygosity (LOH) at microsatellite markers D9S171, IFNA, D9S270, D9S265. | Human | IFN1@ | 3438 | interferon, type 1, cluster | We have analyzed 54 benign melanocytic nevi and 6 DMN for loss of heterozygosity (LOH) at microsatellite markers D9S171, IFNA, D9S270, D9S265. | Human | MLANA | 2315 | melan-A | Forty-five primary malignant melanomas and 71 benign melanocytic nevi were stained with antibodies to Mart-1. We stained benign melanocytic nevi and malignant melanoma with antibodies to melanoma antigen recognized by T cells (Mart-1) to determine if this was useful in differentiating benign from malignant melanocytic neoplasms. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. The presence or absence of staining for Mart-1 antigen cannot be used to differentiate benign melanocytic nevi from malignant melanocytic tumors. | Human | EZH2 | 2146 | enhancer of zeste homolog 2 (Drosophila) | EZH2 protein levels increase incrementally from benign nevi to melanoma, which suggests that EZH2 may play a role in the pathogenesis and progression of melanoma | Human | ETS1 | 2113 | v-ets avian erythroblastosis virus E26 oncogene homolog 1 | A statistically significant difference in the mean labeling intensity of Ets-1 was seen between invasive melanoma and benign melanocytic nevi (P <.0001). Ets-1 expression was statistically assessed by the one-way analysis of variance (ANOVA) comparing the mean labeling intensity of melanoma to benign melanocytic nevi. | Human | EFNB2 | 1948 | ephrin-B2 | Consistent with these experimental data, we found high levels of Lerk-5 mRNA expression in advanced primary malignant melanomas and metastases (n = 22) but significantly lower or undetectable mRNA expression in benign melanocytic nevi (n = 9; P < 0.001). | Human | CD34 | 947 | CD34 molecule | The normal dermis and benign melanocytic nevi showed numerous CD34(+) fibrocytes, whereas malignant melanomas were devoid of this cell type | Human | BRAF | 673 | v-raf murine sarcoma viral oncogene homolog B | BRAF T1976A mutation is present at high frequency in benign naevi such as Spitz and Reed To investigate the stage in which those mutations occur in the currently proposed sequential malignant transformation of melanocytes, 22 benign melanocytic nevi, 23 melanocytic atypical nevi, and 25 primary cutaneous melanoma from 63 different patients were examined for BRAF mutations using DNA extracted from microdissected formalin-fixed and paraffin-embedded tissues, and a two-round PCR-RFLP-based strategy. Recently, reciprocal activating mutations of NRAS and BRAF were found in benign melanocytic nevi and cutaneous melanomas. |
|